U.S., Nov. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07242417) titled 'TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors' on Nov. 17.
Brief Summary: This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of TC-G203 in patients with GPC3-positive recurrent or metastatic solid tumors who have progressed after prior therapies. The primary objective is to determine the maximum tolerated dose (MTD), with a secondary aim to assess preliminary clinical efficacy in solid tumors.
Study Start Date: Nov. 18
Study Type: INTERVENTIONAL
Condition:
Solid Tumor Cancer
Intervention:
BIOLOGICAL: TC-G203 cells treatment...